HealthQuill Cardiovascular Death
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%, according to a statement from the Indianapolis-headquartered firm.
Drugs Health Pharma

Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.

Read More